Drug Therapy for the Management of Atrial Fibrillation: An Update

Andrew RJ Mitchell


Br J Cardiol. 2003;10(5) 

In This Article

Prevention of Paroxysmal Atrial Fibrillation

The current European guidelines for the prevention of paroxysmal AF suggest that drug therapy should be patient-tailored depending on the underlying aetiology.[4] Anti-arrhythmics of classes 1A, 1C and III are associated with increased sinus rhythm at follow-up in comparison with placebo.[5] In the absence of structural heart disease, class 1C drugs are believed to be the safest. Patients with vagal-mediated AF may respond to flecainide or disopyramide. Beta blockers should be considered in patients with co-existing coronary artery disease, either amiodarone or dofetilide should be used in patients with heart failure and patients with severe left ventricular hypertrophy should be treated with amiodarone.[6]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: